|Base Year Market Size
|USD 30.78 Billion
|Forecast Year Market Size
|USD 54.25 Billion
|Fastest Growing Market
The global medical biomimetics market size was valued at USD 30.78 billion in 2022 and is projected to reach USD 54.25 billion by 2031, registering a CAGR of 6.5% during the forecast period (2023-2031). The medical biomimetics market share has increased as the prevalence of heart disease and dental disease has increased.
Medical biomimetics, also known as biomimicry or bioinspired technology, is a field that designs and develops innovative medical treatments, devices, and technologies by drawing inspiration from nature. It entails researching biological systems and processes in live species such as animals, plants, and microorganisms and then utilizing natural principles and designs to solve medical and healthcare problems. This strategy takes advantage of natural solutions' efficiency, versatility, and elegance to develop innovative goods and therapies. Over the last few years, there have been encouraging advancements in creating surgical equipment. These biomimicry-inspired surgical implements have traits like cutting, stinging, sucking, and gripping found in hands, feet, and mouths.
The rising demand for implants and prostheses to meet the demand for organ transplantation, particularly among older people, is a major driver of the medical biomimetics market. Medical biomimetics is essential since it is often assumed that no design breakthrough is conceivable unless nature is used as a potential model. Medical biomimetics market growth is expected to increase in the coming years due to the recent application of biomimetic technologies for organ regeneration.
The rising prevalence of chronic conditions such as cardiovascular disease in developed and developing economies is expected to drive the global market over the forecast period. For example, according to data provided by the Centers for Disease Control and Prevention- a science-based, data-driven service organization that protects the public's health in the United States- on May 15, 2023, coronary artery diseases are among the most common type of heart disease in the United States, accounting for nearly 695,000 deaths in 2021.
Furthermore, cancer is frequently a chronic condition that necessitates long-term therapy. Biomimetic nanoparticles and drug delivery systems mimic natural processes to target cancer cells precisely, lowering side effects and boosting cancer therapy efficacy. Cancer is one of the top causes of morbidity and mortality globally, according to the World Cancer Research Fund, with an expected 19.3 million new cases and 10 million cancer-related deaths in 2020. Biomimetic methods for cancer treatment can potentially increase cancer patients' quality of life and improve treatment outcomes. Chronic diseases' global incidence and effects constitute an enticing global medical biomimetics market trends.
The need to meet stringent regulatory criteria and safety standards is a significant restriction in the worldwide medical biomimetics market. Developing and bringing biomimetic medical technology to market necessitates compliance with numerous rules and gaining regulatory licenses. This procedure can be time-consuming, costly, and difficult. Regulatory licenses for medical devices, including biomimetic technology, are often granted by bodies such as the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) in Europe. To support the safety and efficacy of medical devices, these authorities demand considerable data and proof.
Aside from time, the expense of acquiring regulatory approvals might be significant. In the United States, for example, the Medical Device Manufacturers Association (MDMA) reported that the average cost of obtaining a high-risk medical device through the FDA's pre-market approval (PMA) procedure would be more than USD 94 million in 2022.
Biomimetic technologies provide a fantastic chance to develop diagnostic tools, resulting in a more accurate and early illness diagnosis. Improved diagnostics can enhance patient prognosis and the efficacy of medical treatments dramatically. The echolocation skills of bats and dolphins inspired biomimetic ultrasound and sonar technologies. Sound waves are used in these technologies to create high-resolution pictures of interior structures. These new diagnostic technologies can discover defects and diseases early by emulating the precision of natural echolocation.
Furthermore, biomimetic methods have been used to improve MRI contrast and specificity. Researchers have produced contrast agents that replicate the magnetic properties of particular organisms, such as marine critters. Biomimetic contrast compounds allow for more precise and detailed imaging of tissues and organs. Multiple scientific articles and conferences have highlighted advances in biomimetic MRI contrast agents, emphasizing their potential to improve the diagnostic capabilities of this extensively used imaging method.
The global medical biomimetics market analysis is conducted in North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America.
North America is the most significant global market shareholder and is estimated to grow at a healthy CAGR over the forecast period. The region's high R&D activity, high adoption of novel technology, high disposable income, and presence of significant market participants all contribute to the region's large share. The presence of numerous key companies, including BioHorizons, Keystone Dental Group, Curasan, Inc., and Zimmer Biomet, and biomimetics product manufacturing technology advancements in the region fuel market expansion. This is mostly due to increased dental diseases, which need dental biomimetics products, government financing for biomimetics research, and a considerable increase in capital income in industrialized countries.
Furthermore, a sophisticated reimbursement framework to lower expenditure levels encourages market growth. As a result, such factors drive market expansion. Furthermore, the United States is likely to contribute a significant portion of the regional market and fuel the growth of the global market throughout the forecast period. According to the Administration on Aging (AoA), the population aged 65 and over in the United States climbed from 39.6 million in 2009 to 54.1 million in 2019 (a 36% rise) and is expected to reach 94.7 million in 2060. By 2040, there will be approximately 80.8 million older people, more than doubled in 2000. As a result, it is rather evident that the region's growth is attributable to the rising elderly population along with the increasing frequency of chronic disease. Furthermore, market expansion is predicted to be driven by well-established healthcare infrastructure, high purchasing power, and an increased adoption rate of medical biomimetics products.
Asia-Pacific is anticipated to exhibit a healthy CAGR over the forecast period owing to increased investment in medical and healthcare infrastructure, a large patient population, growing awareness and adoption of new technology, and government initiatives to boost the growth of the biotechnology sector. The rise in the number of heart and orthopedic disorders in this region and the rising purchasing power of populated countries such as China and India drive the growth of medical biomimetics. Asia-Pacific countries have a large population base, with India being the most populous, with 1,428,627,663 people in 2023, and China being the second most populous, with 1,425,671,352 people in 2023.
Additionally, according to medical biomimetics market insights, the growing prevalence of heart and dental problems is driving the growth of the global market in Europe. Because medical biomimetics can be used to reconstruct damaged bones, their application is predicted to expand as vehicle accidents increase. Dental biomimetics is also used in dental bone transplant surgeries to increase the density and volume of the jaw in areas where bone loss has occurred.
Europe holds a significant market share. Ischemic heart disease (IHD) and stroke kill more people in Central and Eastern Europe than in Northern, Southern, and Western Europe. Every year in the EU, more than 6 million new instances of CVD are identified, and over 1.7 million people die from circulatory system disorders, accounting for around 37% of all deaths. The high prevalence of CVD and the availability of a technologically advanced healthcare system would increase the adoption of medical biomimetics for its treatment, pushing regional market expansion.
|By Disease Type
|Otsuka Medical Devices Group Stryker Abbott AVINENT Science and Technology SynTouch Inc Osteopore International Pte Ltd Vandstrom Inc Biomimetics Technologies Inc Swedish Biomimetics 3000 ApS Keystone Dental Group LifeMatrix Curasan Inc CorNeat Vision NanoHive Medical LLC Zimmer Biomet.
|U.K. Germany France Spain Italy Russia Nordic Benelux Rest of Europe
|China Korea Japan India Australia Singapore Taiwan South East Asia Rest of Asia-Pacific
|Middle East and Africa
|UAE Turkey Saudi Arabia South Africa Egypt Nigeria Rest of MEA
|Brazil Mexico Argentina Chile Colombia Rest of LATAM
|Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
The global medical biomimetics market is segmented based on disease type, application, and region.
Disease type is further segmented into Ophthalmology, Cardiovascular, Orthopedic, and Dental.
Cardiovascular diseases dominate the market. The cardiovascular sector includes heart and blood vessel disorders and ailments. Biomimetic technologies are used to create solutions replicating the features and functionalities of natural heart and vascular structures and functions. Medical devices utilized in cardiovascular applications include biomimetic heart valves, stents, and vascular grafts. These devices treat illnesses such as cardiac valve dysfunction, atherosclerosis, and aneurysms by mimicking natural structures. CVD is the leading cause of death worldwide, accounting for 17.9 million deaths annually. Every year, almost 2.1 million patients worldwide receive CVD implants to avert death. Furthermore, introducing technologically improved items, in conjunction with government funding, provides attractive potential for the segment during the projection period.
The goal of orthopedic biomimetics is to treat musculoskeletal problems and injuries. The goal is to develop implants and devices that mimic the biomechanical qualities of native bone and joint structures to promote healing and mobility. In orthopedic applications, biomimetic joint prostheses, bone scaffolds, and ligament replacements are used. These devices are intended to restore natural joint function and movement.
The segment can be bifurcated by application into Wound healing, tissue engineering, and drug delivery.
Wound healing holds the largest medical biomimetics market share. Biomimetic wound healing mimics the natural mechanisms during tissue repair and regeneration. These technologies aim to speed up wound healing, reduce scarring, and lower the risk of infection. Biomimetic wound dressings, bandages, and skin grafts stimulate the body's natural wound-healing processes. They enhance cell development and tissue regeneration, making wound healing faster and more effective. The need for wound healing and wound care products is increasing due to increased surgical cases and the global incidence of chronic diseases. Furthermore, the segment will continue to rise due to demographic trends such as an aging population, growing diabetes and obesity rates, and increased sensitivity to non-healing chronic wounds.
Biomimetic drug delivery systems are intended to mimic the body's natural methods for medicine delivery. These technologies improve drug administration precision, efficiency, and safety. The medication delivery segment is expected to grow rapidly during the forecast period in the market for medical biomimetics. This can be ascribed to patient preferences for improved medication administration methods and increased research and development.